Peptide YY

Mechanism of Action

Peptide YY (PYY) is a gut hormone that acts as a key regulator of food intake and metabolism through several physiological pathways. Based on the available evidence, PYY functions primarily as a satiety signal, though the specific molecular mechanisms require further investigation.

PYY is released by enteroendocrine L-cells in the intestine, particularly in response to food intake. The evidence suggests that PYY expression can be modulated therapeutically for controlling overweight and obesity, indicating its role in energy homeostasis regulation. However, the provided research does not contain detailed molecular-level mechanisms describing exactly how PYY binds to specific receptors or the downstream signaling cascades involved.

The hormone appears to interact with both homeostatic and hedonic systems that control food intake, based on clinical trial data examining energy restriction combined with interventions that may influence gut hormone responses. Additionally, there is evidence suggesting PYY may be involved in gut microbiome-hormone interactions, potentially influencing cardiovascular risk factors, though the precise molecular pathways of these interactions are not detailed in the available evidence.

Studies have also examined PYY in the context of various surgical interventions, including bariatric surgery, suggesting the hormone plays a role in the metabolic changes observed after gastrointestinal procedures. However, the specific mechanisms by which surgical alterations to the gut affect PYY signaling pathways are not clearly described in the provided evidence.

Important limitation: The available evidence provides limited detail about PYY's specific molecular mechanisms of action, receptor binding properties, or detailed signaling pathways. More comprehensive research would be needed to fully characterize how PYY works at the cellular and molecular level.

This information is for educational purposes only and should not be considered personalized medical advice. Consult with healthcare professionals for medical guidance.

Peptide YY (PYY) is primarily being investigated for its role in appetite regulation and metabolic health, with emerging research exploring its potential in various clinical contexts.

Obesity and Weight Management

The primary clinical focus for PYY involves its therapeutic potential in controlling overweight and obesity. A 2026 narrative review highlighted the promise of modulating endogenous PYY expression as a strategy for weight management, though specific clinical outcomes from this review are not detailed in the available evidence.

Clinical trials have examined PYY responses in various dietary and surgical contexts related to obesity:

• Studies have investigated L-cell activity (which produces PYY) in the small intestine following Roux-en-Y gastric bypass (RYGBP) surgery in obese patients with diabetes
• Research has examined gut hormone responses, including PYY, after consumption of Paleolithic-type meals
• Trials have explored the relationship between PYY and other appetite-regulating factors in adolescents

Metabolic Disorders

Limited evidence suggests potential applications in metabolic health:

• A 2026 study examined the relationship between appetite hormones (including PYY) and body mass index in children with intoxication-type metabolic diseases, though specific findings are not provided in the available evidence
• Research has investigated PYY alongside other gut hormones in the context of glucose homeostasis and dietary interventions

Gastrointestinal Applications

PYY has been studied in relation to:

• Food intake and gut hormone responses in patients who have undergone upper gastrointestinal surgery for cancer
• Intestinal motility and barrier function, as suggested by research on gut microbiota interactions that may influence PYY production

Safety and Pharmacokinetics

A completed Phase 1 safety and pharmacokinetic study (NCT01515319) examined a PYY-related compound (Y242) in adult subjects, indicating clinical development efforts, though specific safety or efficacy outcomes are not provided in the available evidence.

Important Limitation: The current evidence base provides limited detail on specific clinical outcomes, efficacy measures, or safety profiles for PYY interventions. Most studies appear to be in early phases or focus on mechanistic understanding rather than established therapeutic applications.

This information is for educational purposes only and should not replace consultation with healthcare providers for medical advice.

Safety Profile of Peptide YY

Evidence Limitation: The available evidence provides very limited information specifically about the safety profile of peptide YY (PYY) as a therapeutic compound. Most of the provided studies focus on endogenous PYY levels in various populations or dietary interventions that affect PYY, rather than direct administration of PYY as a treatment.

Known Side Effects

The evidence provided does not contain specific information about side effects from PYY administration. One clinical trial (NCT01515319) was identified as a "Safety and Pharmacokinetic Study of Y242" in adult subjects, but the results and safety findings are not included in the available evidence.

Contraindications

No specific contraindications for PYY therapy are documented in the provided evidence.

Drug Interactions

The available evidence does not provide information about drug interactions with PYY.

Populations That Should Avoid PYY

Based on the limited evidence provided:

• Pregnant and breastfeeding women: No safety data is available for these populations
• Children: While some studies examined PYY levels in children with metabolic diseases, no safety data for PYY administration in pediatric populations is provided
• Patients with specific medical conditions: The evidence does not specify which medical conditions might contraindicate PYY use

Research Gaps

The evidence base for PYY safety is notably thin. While several studies examine endogenous PYY levels and responses to dietary interventions, there is insufficient published safety data from clinical trials involving direct PYY administration. The completed Phase 1 safety study mentioned (NCT01515319) could potentially provide relevant safety information, but the results are not included in the available evidence.

Medical Disclaimer: This information is for educational purposes only and should not be used for medical decision-making. Patients considering any PYY-based therapy should consult with their healthcare provider to discuss potential risks, benefits, and individual considerations.

Research Papers and Clinical Trials

The research on peptide YY (PYY) encompasses several key areas, though the available evidence is limited and comes from varied study approaches.

Therapeutic Potential and Mechanisms

A 2026 narrative review examined the therapeutic potential of modulating endogenous PYY expression for controlling overweight and obesity (PMID: 42325510). This review synthesized existing knowledge about PYY's role as an appetite-regulating hormone, though specific study details and sample sizes were not provided in the available evidence.

Dietary Interventions and PYY Response

One completed clinical trial (NCT01999504) investigated gut hormone responses, including PYY, after consuming paleolithic-type meals, though the study design, sample size, and results are not detailed in the available information.

A 2026 study published in the Journal of Obesity examined how a healthy diet intervention affected food preferences and eating behaviors (PMID: 42318824). While this study looked at appetite-related outcomes, it found no changes in adipokines or glucose homeostasis, suggesting that dietary interventions may have limited effects on some metabolic parameters.

Clinical Populations and Disease States

Research has explored PYY in specific patient populations. One completed observational study (NCT02385617) examined food intake and gut hormones, including PYY, in patients who underwent upper gastrointestinal surgery for cancer.

A 2026 study in the Orphanet Journal of Rare Diseases investigated the relationship between appetite hormones and body mass index in children with intoxication-type metabolic diseases (PMID: 42316233), though specific findings were not detailed in the available evidence.

Surgical Interventions

One clinical study (NCT05446415) is examining L-cell activity in the small intestine in obese patients with type 2 diabetes who underwent Roux-en-Y gastric bypass (RYGBP), focusing on the biliopancreatic loop's role. The status of this study is unknown.

Pharmaceutical Development

A completed Phase 1 safety and pharmacokinetic study (NCT01515319) evaluated Y242 in adult subjects, though this compound's relationship to PYY and study outcomes are not specified in the available information.

Limitations

The current evidence base is limited, with many studies lacking detailed methodology, sample sizes, or results in the provided information. Most research appears to be in early phases, and the clinical applications of PYY modulation remain under investigation.

Note: This synthesis is based solely on the limited evidence provided and should not be considered comprehensive medical advice. Consult healthcare professionals for personalized treatment decisions.

Protocols

The available literature does not provide specific dosing or administration protocols for exogenous Peptide YY (PYY) therapy. The evidence primarily focuses on endogenous PYY modulation through dietary interventions, probiotics, and surgical procedures rather than direct peptide administration.

Endogenous PYY Modulation Approaches

Most studies investigate ways to naturally enhance endogenous PYY production rather than direct peptide administration:

• Dietary interventions: Research examines how specific meal compositions (such as Paleolithic-type meals) affect natural PYY release
• Probiotic supplementation: Studies explore how certain bacterial strains may influence PYY levels as part of gut hormone regulation
• Surgical interventions: Bariatric procedures like Roux-en-Y gastric bypass are studied for their effects on PYY secretion

Limited Clinical Development Data

One Phase 1 safety and pharmacokinetic study (NCT01515319) investigated a compound called "Y242" in adult subjects, but specific dosing protocols and outcomes are not detailed in the available evidence.

Research Context

The current literature suggests that therapeutic approaches focus primarily on modulating the body's natural PYY production rather than direct peptide replacement or supplementation therapy. Studies examine PYY as a biomarker of treatment response rather than as a direct therapeutic target.

---

Disclaimer: This information is for educational purposes only and represents research findings rather than clinical recommendations. This is not personalized medical advice. Any consideration of PYY-related interventions should be discussed with qualified healthcare providers who can evaluate individual medical circumstances and provide appropriate guidance based on current clinical protocols and safety data.

Outcomes Summary for Peptide YY

The evidence for measurable outcomes related to peptide YY (PYY) interventions is limited, with most available data coming from observational studies rather than direct therapeutic trials.

Measured Biomarker Changes

The literature reports PYY as a measurable biomarker in several contexts:

• Gut hormone response studies: PYY levels have been measured following different dietary interventions, including paleolithic-type meals, though specific numerical outcomes are not detailed in the available evidence
• Post-surgical monitoring: PYY concentrations are tracked in patients following upper gastrointestinal surgery for cancer, suggesting its utility as a biomarker for gut function recovery
• Metabolic disease assessment: PYY levels are correlated with body mass index in pediatric patients with metabolic diseases, indicating its potential as a diagnostic or monitoring marker

Clinical Outcomes

Weight and Metabolic Parameters:

• Studies examine PYY's relationship to obesity management and metabolic control, particularly in the context of bariatric surgery and dietary interventions
• The strength of evidence for direct therapeutic effects remains unclear from the available abstracts

Gastrointestinal Function:

• PYY is measured as an indicator of intestinal motility and barrier function in animal models
• Clinical trials have assessed PYY response in post-surgical patients, though specific outcome measures are not detailed

Strength of Evidence Limitations

The current evidence base has significant limitations:

• Most studies appear to measure PYY as a biomarker rather than evaluate it as a direct therapeutic intervention
• Available abstracts lack specific numerical outcomes, effect sizes, or statistical significance data
• The completed clinical trials listed do not clearly indicate successful PYY-based interventions
• Much of the mechanistic evidence comes from animal studies rather than human trials

Disclaimer: This summary is based on limited available evidence and should not be used for medical decision-making. Consult healthcare providers for personalized medical advice regarding PYY-related treatments or assessments.